茵陈苓桂剂对非酒精性脂肪性肝炎大鼠胰岛素抵抗的影响

李峰; 谢春娥; 胡世平; 吴迪; 薛晓轩; 李军祥; 王允亮; 李晓红; 袁亚利; 王乾皓

doi:10.3969/j.issn.1671-038X.2021.12.004

茵陈苓桂剂对非酒精性脂肪性肝炎大鼠胰岛素抵抗的影响

- 1. 北京中医药大学深圳医院(龙岗)肝病科(广东深圳, 518100);
- 2. 北京中医药大学东方医院脾胃肝胆科;
- 3. 北京中医药大学研究生院
基金项目:
北京中医药大学科研创新团队项目（No：2019-JYB-TD004）；北京中医药大学在读研究生项目（No：2019-JYB-XS-214）

详细信息

通讯作者: 谢春娥,E-mail:xiechune@sina.com

中图分类号: R575.1

收稿日期: 2020-12-25

Effect of Yinchen Linggui Prescription on insulin resistance in nonalcoholic steatohepatitis rats

- 1. Department of Liver Diseases, Shenzhen Hospital[Longgang], Beijing University of Chinese Medicine, Shenzhen, 518100, China;
- 2. Department of Spleen, Stomach and Hepatobiliary, Dongfang Hospital, Beijing University of Chinese Medicine;
- 3. Graduate School of Beijing University of Chinese Medicine

More Information

Corresponding author: XIE Chun'e, E-mail: xiechune@sina.com

Received Date: 25 December 2020

摘要

摘要: 目的：观察茵陈苓桂剂对非酒精性脂肪性肝炎（NASH）大鼠胰岛素抵抗的影响，探讨茵陈苓桂剂对NASH大鼠的作用机制。方法：将60只SPF级雄性SD大鼠适应性喂养7 d后，随机分成正常组（10只）和造模组（50只），正常组予以普通饲料喂养，造模组予以高脂饲料喂养8周；在造模组中随机取2只大鼠，确定造模成功后，再将造模组剩下的48只大鼠随机分为模型组（8只）、茵陈苓桂剂高剂量组（10只）、茵陈苓桂剂中剂量组（10只）、茵陈苓桂剂低剂量组（10只）和多烯磷脂酰胆碱组（10只）；予对应灌胃药物给药4周。测定大鼠的体重和肝湿重以计算肝指数，测量大鼠空腹血清葡萄糖（GLU）含量和用ELISA测定胰岛素（INS）水平，来计算胰岛素抵抗指数（HOMA-IR）。用生化法检测大鼠丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、总胆固醇（T-CHO）和甘油三酯（TG）含量；ELISA测定大鼠游离脂肪酸（FFA）、瘦素（LEP）、脂联素（APN）水平。结果：与正常组比较，模型组大鼠的肝指数、HOMA-IR及大鼠血清ALT、AST、T-CHO、TG、FFA水平显著增高（P<0.01），血清及肝组织匀浆LEP水平显著升高（P<0.01），APN水平显著降低（P<0.01）。与模型组比较，多烯磷脂酰胆碱组及茵陈苓桂剂各剂量组大鼠肝指数、HOMA-IR值及大鼠血清AST、T-CHO水平显著降低（P<0.01或P<0.05），血清APN水平显著升高（P<0.01或P<0.05）；多烯磷脂酰胆碱组及茵陈苓桂剂高、中剂量组大鼠ALT、TG水平均显著性降低（P<0.01或P<0.05），肝组织匀浆APN水平显著升高（P<0.01）；多烯磷脂酰胆碱组及茵陈苓桂剂高剂量组大鼠血清FFA水平显著降低（P<0.01）。在血清及肝组织匀浆LEP含量方面，多烯磷脂酰胆碱组大鼠与模型组比较显著降低（P<0.01或P<0.05）；而茵陈苓桂剂对于NASH大鼠血清及肝组织匀浆LEP水平的影响差异无统计学意义（P>0.05）。结论：茵陈苓桂剂能够通过改善肝指数、HOMA-IR及ALT、AST、T-CHO、TG、FFA水平，调控血清及肝组织匀浆APN含量，降低胰岛素抵抗，而达到防治NASH的目的。
- 茵陈苓桂剂 /
- 非酒精性脂肪性肝炎 /
- 胰岛素抵抗 /
- 瘦素 /
- 脂联素
Abstract: Objective: Observation of the effect of Yinchen Linggui Prescription on insulin resistance in rats with nonalcoholic steatohepatitis(NASH). To explore the mechanism of action of Yinchen Linggui prescription on NASH rats. Methods: After 60 SPF male SD rats were fed adaptively for 7 days, they were randomly divided into normal group(10) and model group(50). The normal group was fed with normal feed and the model was fed with high-fat feed for 8 weeks. Randomly take 2 rats in the model, and determine the success of the model, then randomly divide the remaining 48 rats in the model into the model group(8), Yinchen Linggui Prescription high-dose group(10), Yinchen Linggui Prescription medium-dose group(10), Yinchen Linggui Prescription low-dose group(10), and polyene phosphatidylcholine group(10); corresponding drugs were given for 4 weeks. The body mass and wet liver weight of the rats were measured to calculate the liver index. The fasting serum glucose(GLU) content of rats was measured and the insulin(INS) level was measured by ELISA to calculate the insulin resistance index(HOMA-IR). Biochemical methods were used to detect rats alanine aminotransferase(ALT), aspartate aminotransferase(AST), total cholesterol(T-CHO) and triglyceride(triglyceride, TG) content. ELISA measures the levels of free fatty acid(FFA), leptin(LEP) and adiponectin(APN) in rats. Results: Compared with the normal group, the liver index, HOMA-IR and serum ALT, AST, T-CHO, TG, and FFA levels of the model group were significantly increased(P<0.01), and the LEP level of serum and liver tissue homogenate was significantly Increased(P<0.01), APN level was significantly reduced(P<0.01). Compared with the model group, the liver index, HOMA-IR value and serum AST and T-CHO levels of rats in the polyene phosphatidylcholine group and Yinchen Linggui prescription each dose group were significantly reduced(P<0.01 or P<0.05), The serum APN level was significantly increased(P<0.01 or P<0.05); The levels of ALT and TG of rats in the polyene phosphatidylcholine group and Yinchen Linggui Prescription agent high and medium dose groups were significantly reduced(P<0.01 or P<0.05), and the APN level of liver tissue homogenate was significantly increased(P<0.01). The serum FFA level of rats in the polyene phosphatidylcholine group and the Yinchen Linggui Prescription agent high-dose group was significantly reduced(P<0.01). In terms of LEP content in serum and liver tissue homogenate, rats in the polyene phosphatidylcholine group were significantly lower than the model group(P<0.01 or P<0.05). The effect of Yinchen Linggui Prescription on the LEP levels of serum and liver tissue homogenates of NASH rats has not been found to be statistically significant(P>0.05). Conclusion: Yinchen Linggui Prescription can prevent and cure NASH by improving liver index, HOMA-IR and ALT, AST, T-CHO, TG, FFA levels, regulating APN content in serum and liver tissue homogenate, and reducing insulin resistance.
- Yinchen Linggui Prescription /
- non-alcoholic fatty liver disease /
- insulin resistance /
- leptin /
- adiponectin

HTML全文

参考文献(21)

[1]	李军祥, 陈誩, 王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志, 2017, 25(11):805-811.
[2]	Rinella ME.Nonalcoholic fatty liver disease:a systematic review[J].JAMA, 2015, 313(22):2263-2273.
[3]	Diehl AM, Day C.Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J].N Engl J Med, 2017, 377(21):2063-2073.
[4]	Younossi ZM, Koenig AB, Abdelatif D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64(1):73-84.
[5]	吴迪, 李军祥, 谢春娥.基于肝脏超声衰减参数观察茵陈苓桂剂干预非酒精性脂肪性肝炎的作用研究[J].中国中西医结合消化杂志, 2018, 26(10):817-822.
[6]	谢博文, 李蓓蕾, 胡鹏言, 等.非酒精性脂肪性肝病动物模型研究进展[J].广西中医药大学学报, 2018, 21(4):65-67.
[7]	Cote I, Ngo Sock ET, Levy E, et al.An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation:effect of endurance training[J].Euro J Nutrition, 2013, 52(5):1523-1532.
[8]	王春花, 靳丽颖, 王思萌.非酒精性脂肪性肝病动物模型研究进展[J].中国兽医杂志, 2018, 54(5):62-65.
[9]	郭一, 李军祥, 毛堂友, 等.自噬相关蛋白在高脂饲料诱导的非酒精性脂肪性肝炎大鼠肝脏中的表达及茵陈苓桂术甘汤的干预效应[J].中华中医药学刊, 2018, 36(4):798-801.
[10]	樊亚东, 贾建伟, 张晓雨.非酒精性脂肪性肝病发病机制和临床治疗研究进展[J].中西医结合肝病杂志, 2020, 30(1):93-96.
[11]	Kanwar P, Kowdley KV.The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis[J].Clin Liver Dis, 2015, 20(2):225-243.
[12]	Cusi K.Role of obesity and lipotoxicity in the development of non-alcoholic steatohepatitis:pathophysiology and clinical implications[J].Gastroenterology, 2012, 142(4):711-725.
[13]	Zhang X, Xu A, Chung SK, et al.Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against dietinduced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice[J].Diabetes, 2011, 60:486-495.
[14]	蔡冰, 周永健.脂联素及其在非酒精性脂肪性肝病的作用研究进展[J].广州医药, 2014, 45(1):80-82.
[15]	黄晓东.瘦素及脂联素在非酒精性脂肪肝中的表达及意义[D].武汉:武汉大学, 2015.
[16]	罗冬梅, 陶艳艳, 刘成海.非酒精性脂肪性肝炎发病机制和治疗研究进展[J].肝脏, 2020, 25(9):1013-1017.
[17]	中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J].中医杂志, 2017, 58(19):1706-1710.
[18]	刘莹, 张会存, 段娜, 等.茵陈蒿汤对高脂饮食诱导大鼠非酒精性脂肪性肝炎的药效学观察[J].中国实验方剂学杂志, 2012, 18(13):217-222.
[19]	余轶群, 陈希, 李军祥.绞股蓝、生山楂水提物对非酒精性脂肪性肝炎大鼠脂质代谢相关因子的调控作用研究[J].辽宁中医药大学学报, 2012, 14(7):168-170.
[20]	潘勤, 范建高.肠源性高血氨在非酒精性脂肪性肝炎发病中的作用[J].实用肝脏病杂志, 2020, 23(6):761-764.
[21]	Suk KT, Kim DJ.Gut microbiota:Novel therapeutic target for nonalcoholic fatty liver disease[J].Expert Rev Gastroenterol Hepatol, 2019, 13(3):193-204.